Abdominal Adiposity and Cardiometabolic Risk: Do We Have All the Answers?

American Journal of Medicine

Volumn 120, Issue 9 SUPPL. 1, 2007, Pages

  Haffner, Steven M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Abdominal adipose tissue; C reactive protein; Cardiometabolic risk; Metabolic syndrome; Type 2 diabetes mellitus

Indexed keywords

C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CYTOKINE; FIBRINOGEN; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ARTICLE; ATHEROGENESIS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ABDOMINAL FAT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; OBESITY; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 34548040666     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.06.006     Document Type: Article

References (26)

1. Mokdad A.H., Bowman B.A., Ford E.S., Vinicor F., Marks J.S., and Koplan J.P. The continuing epidemics of obesity and diabetes in the United States. JAMA 286 (2001) 1195-1200
2. Mokdad A.H., Ford E.S., Bowman B.A., et al. Diabetes trends in the US, 1990-1998. Diabetes Care 23 (2000) 1278-1283
3. Mokdad A.H., Serdula M.K., Dietz W.H., Bowman B.A., Marks J.S., and Koplan J.P. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 282 (1999) 1519-1522
4. National Institutes of Health. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (2000), National Institutes of Health/National Heart, Lung, and Blood Institute/North American Association for the Study of Obesity, Bethesda, MD October NIH Publication No. 00-4084.
5. Calle E.E., Thun M.J., Petrelli J.M., Rodriguez C., and Heath C.W. Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med 341 (1999) 1097-1105
6. Adams K.F., Schatzkin A., Harris T.B., et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 355 (2006) 763-778
7. Jee S.H., Sull J.W., Park J., et al. Body-mass index and mortality in Korean men and women. N Engl J Med 355 (2006) 779-787
8. Folsom A.R., Kaye S.A., Sellers T.A., et al. Body fat distribution and 5-year risk of death in older women. JAMA 269 (1993) 483-487
9. Banerji M.A., Lebowitz J., Chaiken R.L., Gordon D., Kral J.G., and Lebovitz H.E. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol 273 pt 1 (1997) E425-E432
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
11. International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. [IDF Website.] (2006). http://www.idf.org/webdata/docs/MetSyndrome_FINAL.pdf Available at: http://www.idf.org/webdata/docs/MetSyndrome_FINAL.pdf. Accessed March 13
12. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. [published correction appears in Circulation. 2005;112:e297-e298]. Circulation 112 (2005) 2735-2752
13. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
14. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001) 1844-1850
15. Angulo P., and Lindor K.D. Treatment of non-alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 16 (2002) 797-810
16. Hanley A.J.G., Williams K., Festa A., et al. Elevations in markers of liver injury and risk of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 53 (2004) 2623-2632
17. Hanley A.J.G., Williams K., Festa A., Wagenknecht L.E., D'Agostino R.B., and Haffner S.M. Liver markers and development of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Diabetes 54 (2005) 3140-3147
18. Hunt K.J., Resendez R.G., Williams K., Haffner S.M., and Stern M.P. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110 (2004) 1251-1257
19. Lorenzo C., Okoloise M., Williams K., Stern M.P., and Haffner S.M. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care 26 (2003) 3153-3159
20. Tchernof A., Nolan A., Sites C.K., Ades P.A., and Poehlman E.T. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 105 (2002) 564-569
21. Ziccardi P., Nappo F., Giugliano G., et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial function in obese women after weight loss over one year. Circulation 105 (2002) 804-809
22. Knowler W.C., Barrett-Connor E., Fowler S.E., et al., Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
23. Orchard T.J., Temprosa M., Goldberg R., et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142 (2005) 611-619
24. Després J.-P., Golay A., Sjostrom L., and Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
25. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., and Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight and obese patients. JAMA 295 (2006) 761-775
26. National Institute of Diabetes & Digestive & Kidney Diseases. Look Ahead: Action for Health in Diabetes Study. [NIDDK Website.]. Available at: http://www.niddk.nih.gov/patient/SHOW/lookahead.htm. Accessed July 24, 2006.